<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns="http://purl.org/rss/1.0/"><channel rdf:about="http://www.neurobiologyofaging.org//inpress?rss=yes"><title>Neurobiology of Aging - Articles in Press</title><description>Neurobiology of Aging RSS feed: Articles in Press.    
 
 
 
 Neurobiology of Aging  publishes the results of studies in behavior, biochemistry, cell biology, 
endocrinology, molecular biology, morphology, neurology, neuropathology, pharmacology, physiology and protein chemistry in which the 
primary emphasis involves mechanisms of nervous system changes with age or diseases associated with age. Reviews and primary research 
articles are included, occasionally accompanied by open peer commentary. Letters to the Editor and brief communications are also acceptable. 
Brief reports of highly time-sensitive material are usually treated as rapid communications in which case editorial review is completed 
within six weeks and publication scheduled for the next available issue.  The accepted abbreviation for


 Neurobiology of Aging  
for bibliographic citation is  Neurobiol.Aging 
 
 
   </description><link>http://www.neurobiologyofaging.org//inpress?rss=yes</link><dc:publisher>Elsevier Inc.</dc:publisher><dc:language>en</dc:language><dc:rights> © 2012 Elsevier Inc. All rights reserved. </dc:rights><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:issn>0197-4580</prism:issn><prism:publicationDate>2012-05-16</prism:publicationDate><prism:copyright> © 2012 Elsevier Inc. All rights reserved. </prism:copyright><prism:rightsAgent>healthpermissions@elsevier.com</prism:rightsAgent><items><rdf:Seq><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012002333/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012002382/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012002394/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012002618/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012002606/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012002278/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012002291/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS019745801200231X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012002266/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012002345/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS019745801200228X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012002321/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001960/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012002151/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012002187/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012002308/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012002217/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012002175/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001650/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001984/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS019745801200214X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001807/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001819/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001820/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001959/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001972/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012002163/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001789/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001649/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001790/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001674/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS019745801200173X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001753/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001765/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001546/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001613/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001625/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001741/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001777/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001327/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001510/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001595/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001637/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001662/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001728/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001340/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001352/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001534/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001558/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neurobiologyofaging.org/article/PIIS0197458012001601/abstract?rss=yes"/></rdf:Seq></items></channel><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012002333/abstract?rss=yes"><title>Verbal learning in Alzheimer's disease and mild cognitive impairment: fine-grained acquisition and short-delay consolidation performance and neural correlates - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012002333/abstract?rss=yes</link><description>Abstract: 
The aim of this study was to examine correlations between acquisition and short-delay consolidation and brain metabolism at rest measured by fluorodeoxyglucose positron emission tomography (FDG-PET) in 44 Alzheimer's disease (AD) patients, 16 patients with mild cognitive impairment (MCI) who progressed to dementia (MCI-AD), 15 MCI patients who remained stable (MCI-S, 4–8 years of follow-up), and 20 healthy older participants. Acquisition and short-delay consolidation were calculated respectively as mean gained (MG) and lost (ML) access to items of the California Verbal Learning Task. MG performance suggests that acquisition is impaired in AD patients even at predementia stage (MCI-AD). ML performance suggests that short-delay consolidation is deficient only in confirmed AD patients. Variations in acquisition performance in control participants are related to metabolic activity in the anterior parietal cortex, an area supporting task-positive attentional processes. In contrast, the acquisition deficit is related to decreased activity in the lateral temporal cortex, an area supporting semantic processes, in patients at an early stage of AD and is related to metabolic activity in the hippocampus, an area supporting associative processes, in confirmed AD patients.
</description><dc:title>Verbal learning in Alzheimer's disease and mild cognitive impairment: fine-grained acquisition and short-delay consolidation performance and neural correlates - Corrected Proof</dc:title><dc:creator>Sarah Genon, Fabienne Collette, Chris J.A. Moulin, Françoise Lekeu, Mohamed Ali Bahri, Eric Salmon, Christine Bastin</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.04.004</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-05-16</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-05-16</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012002382/abstract?rss=yes"><title>Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012002382/abstract?rss=yes</link><description>Abstract: 
Type 2 diabetes mellitus is a risk factor of Alzheimer's disease (AD), most likely linked to an impairment of insulin signaling in the brain. Liraglutide, a novel long-lasting glucagon-like peptide 1 (GLP-1) analog, facilitates insulin signaling and shows neuroprotective properties. In the present study, we analyzed the effects of liraglutide on the impairment of learning and memory formation induced by amyloid-β protein (Aβ), and the probable underlying electrophysiological and molecular mechanisms. We found that (1) bilateral intrahippocampal injection of Aβ25–35 resulted in a significant decline of spatial learning and memory of rats in water maze tests, together with a serious depression of in vivo hippocampal late-phase long-term potentiation (L-LTP) in CA1 region of rats; (2) pretreatment with liraglutide effectively and dose-dependently protected against the Aβ25–35-induced impairment of spatial memory and deficit of L-LTP; (3) liraglutide injection also activated cAMP signal pathway in the brain, with a nearly doubled increase in the cAMP contents compared with control. These results strongly suggest that upregulation of GLP-1 signaling in the brain, such as application of liraglutide, may be a novel and promising strategy to ameliorate the learning and memory impairment seen in AD.
</description><dc:title>Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats - Corrected Proof</dc:title><dc:creator>Wei-Na Han, Christian Hölscher, Li Yuan, Wei Yang, Xiao-Hui Wang, Mei-Na Wu, Jin-Shun Qi</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.04.009</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-05-16</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-05-16</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012002394/abstract?rss=yes"><title>p73 haploinsufficiency causes tau hyperphosphorylation and tau kinase dysregulation in mouse models of aging and Alzheimer's disease - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012002394/abstract?rss=yes</link><description>Abstract: 
Haploinsufficiency for the p53 family member p73 causes behavioral and neuroanatomical correlates of neurodegeneration in aging mice, including the appearance of aberrant phospho-tau-positive aggregates. Here, we show that these aggregates and tau hyperphosphorylation, as well as a generalized dysregulation of the tau kinases GSK3β, c-Abl, and Cdk5, occur in the brains of aged p73+⧸− mice. To investigate whether p73 haploinsufficiency therefore represents a general risk factor for tau hyperphosphorylation during neurodegeneration, we crossed the p73+⧸− mice with 2 mouse models of neurodegeneration, TgCRND8+⧸Ø mice that express human mutant amyloid precursor protein, and Pin1−⧸− mice. We show that haploinsufficiency for p73 leads to the early appearance of phospho-tau-positive aggregates, tau hyperphosphorylation, and activation of GSK3β, c-Abl, and Cdk5 in the brains of both of these mouse models. Moreover, p73+⧸−;TgCRND8+⧸Ø mice display a shortened lifespan relative to TgCRND8+⧸Ø mice that are wild type for p73. Thus, p73 is required to protect the murine brain from tau hyperphosphorylation during aging and degeneration.
</description><dc:title>p73 haploinsufficiency causes tau hyperphosphorylation and tau kinase dysregulation in mouse models of aging and Alzheimer's disease - Corrected Proof</dc:title><dc:creator>Gonzalo I. Cancino, Freda D. Miller, David R. Kaplan</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.04.010</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-05-16</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-05-16</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012002618/abstract?rss=yes"><title>Association between physical activity and brain health in older adults - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012002618/abstract?rss=yes</link><description>Abstract: 
In the present cross-sectional study, we examined physical activity (PA) and its possible association with cognitive skills and brain structure in 331 cognitively healthy elderly. Based on the number of self-reported light and hard activities for at least 30 minutes per week, participants were assigned to 4 groups representing different levels of PA. The cognitive skills were assessed by the Mini Mental State Examination score, a verbal fluency task, and the Trail-making test as a measure of visuospatial orientation ability. Participants also underwent a magnetic resonance imaging of the brain. Multiple regression analysis revealed that greater PA was associated with a shorter time to complete the Trail-making test, and higher levels of verbal fluency. Further, the level of self-reported PA was positively correlated with brain volume, white matter, as well as a parietal lobe gray matter volume, situated bilaterally at the precuneus. These present cross-sectional results indicate that PA is a lifestyle factor that is linked to brain structure and function in late life.
</description><dc:title>Association between physical activity and brain health in older adults - Corrected Proof</dc:title><dc:creator>Christian Benedict, Samantha J. Brooks, Joel Kullberg, Richard Nordenskjöld, Jonathan Burgos, Madeleine Le Grevès, Lena Kilander, Elna-Marie Larsson, Lars Johansson, Håkan Ahlström, Lars Lind, Helgi B. Schiöth</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.04.013</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-05-16</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-05-16</prism:publicationDate><prism:section>ORIGINAL ARTICLES</prism:section></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012002606/abstract?rss=yes"><title>Impairment of the septal cholinergic neurons in MPTP-treated A30P α-synuclein mice - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012002606/abstract?rss=yes</link><description>Abstract: 
Dementia in Parkinson's disease (PDD) and dementia with Lewy bodies (DLB) are characterized by loss of acetylcholine (ACh) from cortical areas. Clinical studies report positive effects of acetylcholine esterase (AChE) inhibitors in PDD and dementia with Lewy bodies. We here report that the number of neurons expressing a cholinergic marker in the medial septum-diagonal band of Broca complex decreases in A30P α-synuclein-expressing mice during aging, paralleled by a lower AChE fiber density in the dentate gyrus and in the hippocampal CA1 field. After inducing dopamine depletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP), no acute but a delayed loss of cholinergic neurons and AChE-positive fibers was observed, which was attenuated by L-3,4-dihydroxyphenylalanine (DOPA) treatment. Expression of nerve growth factor (NGF) and tyrosine receptor kinase A (TrkA) genes was upregulated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride-treated wild type mice, but not in A30P α-synuclein expressing animals. In contrast, upregulation of sortilin and p75NTR genes was found in the A30P α-synuclein-expressing mice. These results suggest that dopamine deficiency may contribute to the impairment of the septohippocampal system in patients with PDD and that L-3,4-dihydroxyphenylalanine may not only result in symptomatic treatment of the akinetic-rigid syndrome but may also alleviate the degeneration of basal forebrain cholinergic system and the cognitive decline.
</description><dc:title>Impairment of the septal cholinergic neurons in MPTP-treated A30P α-synuclein mice - Corrected Proof</dc:title><dc:creator>Éva M. Szegő, Tiago F. Outeiro, Pawel Kermer, Jörg B. Schulz</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.04.012</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-05-14</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-05-14</prism:publicationDate><prism:section>ORIGINAL ARTICLES</prism:section></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012002278/abstract?rss=yes"><title>Screening of the TARDBP gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012002278/abstract?rss=yes</link><description>Abstract: 
TAR DNA-binding protein (TARDBP) mutations have been reported in patients with amyotrophic lateral sclerosis (ALS) in different populations. Only a few studies have screened for TARDBP mutations in Chinese populations. Here, we sequenced the coding region of all five TARDBP exons for mutations in 13 familial ALS (FALS) pedigrees and 312 sporadic ALS (SALS) patients of Chinese origin, as well as 245 healthy control subjects. Two heterozygous missense mutations, c.875G&gt;A (p.S292N) and c.1043G&gt;T (p.G348V), were identified in two and one SALS patients, respectively. One synonymous substitution, c.1098C&gt;G (p.A366A), was identified in two SALS patients. None of the substitutions were found in healthy control subjects. In Chinese populations, the estimated frequency of TARDBP mutations in SALS patients (0.73%) is higher than Japanese and lower than White populations, whereas the estimated mutation frequency in superoxide dismutase 1 (SOD1)-negative FALS patients (15.2%) is higher than both Japanese and White populations. Our findings provide an overview of the occurrence of TARDBP mutations in Chinese ALS patients and highlight the importance of TARDBP mutation screening in Chinese ALS patients.
</description><dc:title>Screening of the TARDBP gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin - Corrected Proof</dc:title><dc:creator>Zhang-Yu Zou, Yu Peng, Xin-Ning Wang, Ming-Sheng Liu, Xiao-Guang Li, Li-Ying Cui</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.03.014</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-05-11</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-05-11</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012002291/abstract?rss=yes"><title>Intensity discrimination deficits cause habituation changes in middle-aged Caenorhabditis elegans - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012002291/abstract?rss=yes</link><description>Abstract: 
The ability to learn and remember is critical for all animals to survive in the ever-changing environment. As we age, many of our biological faculties decay and of these, decline in learning and memory can be the most distressing. To carefully define age-dependent changes in learning during reproductive age in the nematode Caenorhabditis elegans, we performed a parametric behavioral study of habituation to nonlocalized mechanical stimuli (petri plate taps) over a range of intensities in middle-aged worms. We found that as worms age (from the onset of reproduction to the end of egg laying), response probability habituation increases (at both 10- and 60-second interstimulus intervals) and that these age-related changes were associated with a decrease in the discrimination between stimuli of different intensities. We also used optogenetics to investigate where these age-dependent changes occur. Our data suggest that the changes occur upstream of mechanosensory neuron depolarization. These data support the idea that declines in stimulus intensity discrimination abilities during aging may be one variable underlying age-related cognitive deficits.
</description><dc:title>Intensity discrimination deficits cause habituation changes in middle-aged Caenorhabditis elegans - Corrected Proof</dc:title><dc:creator>Tiffany A. Timbers, Andrew C. Giles, Evan L. Ardiel, Rex A. Kerr, Catharine H. Rankin</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.03.016</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-05-11</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-05-11</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS019745801200231X/abstract?rss=yes"><title>Autophagy induced by the class III histone deacetylase Sirt1 prevents prion peptide neurotoxicity - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS019745801200231X/abstract?rss=yes</link><description>Abstract: 
Sirtuin 1 (Sirt1) is a class III histone deacetylase that mediates the protective effects of neurons in neurodegenerative disorders, including Alzheimer's and prion disease. However, the mechanism directly involved in neuroprotection is still poorly understood. Recent evidence has demonstrated that activating Sirt1 induces autophagy, and that activating autophagy protects neurons against neurodegenerative disorders by regulating mitochondrial homeostasis. Thus, we focused on the mechanism of the Sirt1-mediated neuroprotective effect that was associated with regulating mitochondrial homeostasis via autophagy. Adenoviral-mediated Sirt1 overexpression prevented prion protein (PrP)(106–126)-induced neurotoxicity via autophagy processing. Moreover, Sirt1-induced autophagy protected against the PrP(106–126)-mediated decrease in the mitochondrial membrane potential value. Additionally, Sirt1 overexpression decreased PrP(106–126)-induced Bax translocation to the mitochondria and cytochrome c release into the cytosol. Sirt1 knockdown using small interfering (si) RNAs induced downregulation of Sirt1 protein expression and sensitized neuron cells to PrP(106–126)-induced cell death and mitochondrial dysfunction. Knockdown of autophagy-related 5 (ATG5) using small interfering RNA decreased autophagy-related 5 and autophagy marker microtubule-associated protein 1 light chain 3-II protein levels and blocked the effect of a Sirt1 activator against PrP(106–126)-induced mitochondrial dysfunction and neurotoxicity. Taken together, this study is the first report demonstrating that autophagy induced by Sirt1 activation plays a pivotal role protecting against prion-induced neuron cell death and also suggests that regulating autophagy including which by Sirt1 activation may be a therapeutic target for neurodegenerative disorders including the prion disease.
</description><dc:title>Autophagy induced by the class III histone deacetylase Sirt1 prevents prion peptide neurotoxicity - Corrected Proof</dc:title><dc:creator>Jae-Kyo Jeong, Myung-Hee Moon, You-Jin Lee, Jae-Won Seol, Sang-Youel Park</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.04.002</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-05-11</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-05-11</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012002266/abstract?rss=yes"><title>ADAM10 expression and promoter haplotype in Alzheimer's disease - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012002266/abstract?rss=yes</link><description>Abstract: 
Alzheimer's disease is confirmed at autopsy according to the accumulation of brain neuritic plaques and neurofibrillary tangles in the brain. Neuritic plaques contain amyloid-β (Aβ) and lower levels of Aβ correspond to an increase in ADAM10 α-secretase activity. ADAM10 α-secretase activity produces a soluble amyloid precursor protein (APP) alpha (sAPPα) product and negates the pathological production of Aβ. In this investigation, it was hypothesized that genetic variation with the ADAM10 promoter is associated with ADAM10 expression levels as well as cerebrospinal fluid sAPPα levels. Results from this investigation suggest that the ADAM10 rs514049-rs653765 C-A promoter haplotype is associated with: (1) higher CSF sAPPα levels in cognitively normal controls compared with Alzheimer's disease (AD) patients, (2) higher postmortem brain hippocampus, but not cerebellum, ADAM10 protein levels in subjects with low plaque scores compared with those with high plaque scores, and (3) higher promoter activity for promoter-only reporter constructs compared with promoter 3' untranslated region (3'UTR) constructs in the human neuroblastoma SHSY5Y cell line, but not in HepG2 or U118 cell lines. Taken together, these findings suggest that ADAM10 expression is modulated according to a promoter haplotype that is influenced in a brain region- and cell type-specific manner.
</description><dc:title>ADAM10 expression and promoter haplotype in Alzheimer's disease - Corrected Proof</dc:title><dc:creator>Lynn M. Bekris, Franziska Lutz, Gail Li, Douglas R. Galasko, Martin R. Farlow, Joseph F. Quinn, Jeffrey A. Kaye, James B. Leverenz, Debby W. Tsuang, Thomas J. Montine, Elaine R. Peskind, Chang-En Yu</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.03.013</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-05-10</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-05-10</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012002345/abstract?rss=yes"><title>Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral sclerosis - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012002345/abstract?rss=yes</link><description>Abstract: 
We recently reported that mutations in the valosin-containing protein (VCP) gene are a cause of 1%–2% of familial amyotrophic lateral sclerosis (ALS) cases, but their role in the pathogenesis of sporadic ALS is unclear. We undertook mutational screening of VCP in 701 sporadic ALS cases. Three pathogenic variants (p.Arg159Cys, p.Asn387Thr, and p.R662C) were found in three U.S. cases, each of whom presented with progressive upper and lower motor neuron signs consistent with definite ALS by El Escorial diagnostic criteria. Our data indicate that VCP mutations may underlie apparently sporadic ALS but account for &lt;1% of this form of disease.
</description><dc:title>Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral sclerosis - Corrected Proof</dc:title><dc:creator>Yevgeniya Abramzon, Janel O. Johnson, Sonja W. Scholz, J.P. Taylor, Maura Brunetti, Andrea Calvo, Jessica Mandrioli, Michael Benatar, Gabriele Mora, Gabriella Restagno, Adriano Chiò, Bryan J. Traynor</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.04.005</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-05-10</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-05-10</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS019745801200228X/abstract?rss=yes"><title>UBQLN2 mutations are rare in French and French–Canadian amyotrophic lateral sclerosis - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS019745801200228X/abstract?rss=yes</link><description>Abstract: 
Mutations in the UBQLN2 gene, which encodes a member of the ubiquitin-like protein family (ubiquilin-2), have been recently identified in patients with dominant X-linked amyotrophic lateral sclerosis (ALS) and ALS with dementia. We report here the sequencing of the UBQLN2 gene in 590 ALS patients of French and French–Canadian ancestry. We identified two novel missense mutations (p.S155N and p.P189T) in two individuals with sporadic ALS. Bioinformatic analysis predicts that these missense mutations affect the normal protein's function. Importantly, these findings further highlight the importance of the proline residues located in the conserved domains of the ubiquilin-2 protein, suggesting that mutations affecting these residues are particularly relevant to the development of ALS. Our findings further support a causative role of the UBQLN2 gene in the pathogenesis of ALS and suggest that UBQLN2 mutations are rare in the French and French–Canadian population.
</description><dc:title>UBQLN2 mutations are rare in French and French–Canadian amyotrophic lateral sclerosis - Corrected Proof</dc:title><dc:creator>Hussein Daoud, Hamid Suhail, Anna Szuto, William Camu, Francois Salachas, Vincent Meininger, Jean-Pierre Bouchard, Nicolas Dupré, Patrick A. Dion, Guy A. Rouleau</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.03.015</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-05-07</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-05-07</prism:publicationDate><prism:section>BRIEF COMMUNICATION</prism:section></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012002321/abstract?rss=yes"><title>Hippocampus neuronal metabolic gene expression outperforms whole tissue data in accurately predicting Alzheimer's disease progression - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012002321/abstract?rss=yes</link><description>Abstract: 
Numerous metabolic alterations are associated with the impairment of brain cells in Alzheimer's disease (AD). Here we use gene expression microarrays of both whole hippocampus tissue and hippocampal neurons of AD patients to investigate the ability of metabolic gene expression to predict AD progression and its cognitive decline. We find that the prediction accuracy of different AD stages is markedly higher when using neuronal expression data (0.9) than when using whole tissue expression (0.76). Furthermore, the metabolic genes' expression is shown to be as effective in predicting AD severity as the entire gene list. Remarkably, a regression model from hippocampal metabolic gene expression leads to a marked correlation of 0.57 with the Mini-Mental State Examination cognitive score. Notably, the expression of top predictive neuronal genes in AD is significantly higher than that of other metabolic genes in the brains of healthy subjects. All together, the analyses point to a subset of metabolic genes that is strongly associated with normal brain functioning and whose disruption plays a major role in AD.
</description><dc:title>Hippocampus neuronal metabolic gene expression outperforms whole tissue data in accurately predicting Alzheimer's disease progression - Corrected Proof</dc:title><dc:creator>Shiri Stempler, Yedael Y. Waldman, Lior Wolf, Eytan Ruppin</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.04.003</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-05-07</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-05-07</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001960/abstract?rss=yes"><title>Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer's disease - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001960/abstract?rss=yes</link><description>Abstract: 
Although neuritic plaques and neurofibrillary tangles in older adults are correlated with cognitive impairment and severity of dementia, it has long been recognized that the relationship is imperfect, as some people exhibit normal cognition despite high levels of Alzheimer's disease (AD) pathology. We compared the cellular, synaptic, and biochemical composition of midfrontal cortices in female subjects from the Religious Orders Study who were stratified into three subgroups: (1) pathological AD with normal cognition (“AD-Resilient”), (2) pathological AD with AD-typical dementia (“AD-Dementia”), and (3) pathologically normal with normal cognition (“Normal Comparison”). The AD-Resilient group exhibited preserved densities of synaptophysin-labeled presynaptic terminals and synaptopodin-labeled dendritic spines compared with the AD-Dementia group, and increased densities of glial fibrillary acidic protein astrocytes compared with both the AD-Dementia and Normal Comparison groups. Further, in a discovery-type antibody microarray protein analysis, we identified a number of candidate protein abnormalities that were associated with a particular diagnostic group. These data characterize cellular and synaptic features and identify novel biochemical targets that may be associated with resilient cognitive brain aging in the setting of pathological AD.
</description><dc:title>Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer's disease - Corrected Proof</dc:title><dc:creator>Steven E. Arnold, Natalia Louneva, Kajia Cao, Li-San Wang, Li-Ying Han, David A. Wolk, Selamawit Negash, Sue E. Leurgans, Julie A. Schneider, Aron S. Buchman, Robert S. Wilson, David A. Bennett</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.03.004</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-05-03</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-05-03</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012002151/abstract?rss=yes"><title>Retinal function and CFH-ARMS2 polymorphisms analysis: a pilot study in Italian AMD patients - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012002151/abstract?rss=yes</link><description>Abstract: 
Two major susceptibility genes, complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2), have been implicated in age-related macular degeneration (AMD) pathogenesis. We analyzed the association between CFH rs1061170 and/or ARMS2 rs10490924 polymorphisms with central retinal function properties, as evaluated by focal electroretinogram (fERG). Forty early AMD patients, with preserved visual acuity and typical macular lesions, underwent fERG recording (in response to 41 Hz flicker stimuli presented to the central 18 degrees) and CFH/ARMS2 genotyping. Mean fERG amplitude and sensitivity decreased in patients carrying CFH rs1061170 polymorphism (p &lt; 0.01), compared with wild type ones, although visual acuity and funduscopic features were similar across the 2 groups. No significant fERG phase changes were observed. No association was detected between ARMS2 (rs10490924) polymorphism and fERG parameters. Our findings indicate that CFH (rs1061170) polymorphism impacts significantly on retinal function in early AMD patients, and support the hypothesis that dysfunctional CFH might result in early retinal function loss due to a reduction in the immune antioxidant defense mechanism.
</description><dc:title>Retinal function and CFH-ARMS2 polymorphisms analysis: a pilot study in Italian AMD patients - Corrected Proof</dc:title><dc:creator>Ettore Capoluongo, Paola Concolino, Marco Piccardi, Dario Marangoni, Enrica Mello, Angelo Maria Minnella, Cristina Savastano, Antonello Fadda, Cecilia Zuppi, Silvia Bisti, Benedetto Falsini</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.03.008</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-05-03</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-05-03</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012002187/abstract?rss=yes"><title>Effects of aging on neural connectivity underlying selective memory for emotional scenes - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012002187/abstract?rss=yes</link><description>Abstract: 
Older adults show age-related reductions in memory for neutral items within complex visual scenes, but just like young adults, older adults exhibit a memory advantage for emotional items within scenes compared with the background scene information. The present study examined young and older adults' encoding-stage effective connectivity for selective memory of emotional items versus memory for both the emotional item and its background. In a functional magnetic resonance imaging (fMRI) study, participants viewed scenes containing either positive or negative items within neutral backgrounds. Outside the scanner, participants completed a memory test for items and backgrounds. Irrespective of scene content being emotionally positive or negative, older adults had stronger positive connections among frontal regions and from frontal regions to medial temporal lobe structures than did young adults, especially when items and backgrounds were subsequently remembered. These results suggest there are differences between young and older adults' connectivity accompanying the encoding of emotional scenes. Older adults may require more frontal connectivity to encode all elements of a scene rather than just encoding the emotional item.
</description><dc:title>Effects of aging on neural connectivity underlying selective memory for emotional scenes - Corrected Proof</dc:title><dc:creator>Jill D. Waring, Donna Rose Addis, Elizabeth A. Kensinger</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.03.011</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-30</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-30</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012002308/abstract?rss=yes"><title>Gene dose of apolipoprotein E and age-related hearing loss - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012002308/abstract?rss=yes</link><description>Abstract: 
Next to outer hair cell dysfunction, age-related hearing loss may be explained by apolipoprotein E (APOE) genotype. In the Leiden 85-plus Study, a population-based study, the participants were 85 years old. We measured hearing loss by pure-tone audiometry in 435 participants in relation to APOE. Results demonstrated that those with the APOE-ε4/ε4 genotype had the highest levels of hearing loss (n = 6; 56.1 dB), those with the APOE-ε3/ε4 or ε2/ε4 genotype (n = 89) had intermediate levels of hearing loss (51.0 dB), and those without the APOE-ε4 allele (n = 340) had the lowest levels of hearing loss (48.9 dB), p for trend = 0.02. Eighty percent of participants had hearing loss of 35 dB and more, that is, hearing impairment. The APOE-ε4 allele was associated with a 2.0-fold increased risk of hearing impairment (confidence interval [CI 95%], 1.0–4.0), compared with those without the APOE-ε4 allele. The risk for hearing impairment in subjects with the APOE-ε4 allele remained similar after adjustment for cardiovascular disease, stroke, and cognitive impairment. Our results suggest that the APOE-ε4 allele contributes to age-related hearing loss.
</description><dc:title>Gene dose of apolipoprotein E and age-related hearing loss - Corrected Proof</dc:title><dc:creator>Clara Kurniawan, Rudi G.J. Westendorp, Anton J.M. de Craen, Jacobijn Gussekloo, Jan de Laat, Eric van Exel</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.04.001</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-30</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-30</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012002217/abstract?rss=yes"><title>Control of Aβ release from human neurons by differentiation status and RET signaling - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012002217/abstract?rss=yes</link><description>Abstract: 
Few studies have compared the processing of endogenous human amyloid precursor protein (APP) in younger and older neurons. Here, we characterized LUHMES cells as a human model to study Alzheimer's disease-related processes during neuronal maturation and aging. Differentiated LUHMES expressed and spontaneously processed APP via the secretase pathways, and they secreted amyloid β (Aβ) peptide. This was inhibited by cholesterol depletion or secretase inhibition, but not by block of tau phosphorylation. In vitro aged cells increased Aβ secretion without upregulation of APP or secretases. We identified the medium constituent glial cell line-derived neurotrophic factor (GDNF) as responsible for this effect. GDNF-triggered Aβ release was associated with rapid upregulation of the GDNF coreceptor “rearranged during transfection” (RET). Other direct (neurturin) or indirect (nerve growth factor) RET activators also increased Aβ, whereas different neurotrophins were ineffective. Downstream of RET, we found activation of protein kinase B (AKT) to be involved. Accordingly, inhibitors of the AKT regulator phosphatidylinositol-3-kinase completely blocked GDNF-triggered AKT phosphorylation and Aβ increase. This suggests that RET signaling affects Aβ release from aging neurons.
</description><dc:title>Control of Aβ release from human neurons by differentiation status and RET signaling - Corrected Proof</dc:title><dc:creator>Diana Scholz, Yana Chernyshova, Marcel Leist</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.03.012</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-26</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-26</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012002175/abstract?rss=yes"><title>Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012002175/abstract?rss=yes</link><description>Abstract: 
Medial temporal lobe atrophy (MTA) and cerebrospinal fluid (CSF) markers of Alzheimer's disease (AD) pathology may aid the early detection of AD in mild cognitive impairment (MCI). However, the relationship between structural and pathological markers is not well understood. Furthermore, while posterior atrophy (PA) is well recognized in AD, its value in predicting conversion from late-onset amnestic MCI to AD is unclear. In this study we used visual ratings of MTA and PA to assess their value in predicting conversion to AD in 394 MCI patients. The relationship of atrophy patterns with CSF Aβ1–42, tau, and p-tau(181) was further investigated in 114 controls, 192 MCI, and 99 AD patients. There was a strong association of MTA ratings with conversion to AD (p &lt; 0.001), with a weaker association for PA ratings (p = 0.047). Specific associations between visual ratings and CSF biomarkers were found; MTA was associated with lower levels of Aβ1–42 in MCI, while PA was associated with elevated levels of tau in MCI and AD, which may reflect widespread neuronal loss including posterior regions. These findings suggest both that posterior atrophy may predict conversion to AD in late-onset MCI, and that there may be differential relationships between CSF biomarkers and regional atrophy patterns.
</description><dc:title>Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers - Corrected Proof</dc:title><dc:creator>Manja Lehmann, Esther L. Koedam, Josephine Barnes, Jonathan W. Bartlett, Frederik Barkhof, Mike P. Wattjes, Jonathan M. Schott, Philip Scheltens, Nick C. Fox, Alzheimer's Disease Neuroimaging Initiative</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.03.010</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-20</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-20</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001650/abstract?rss=yes"><title>Identification of PSEN1 and PSEN2 gene mutations and variants in Turkish dementia patients - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001650/abstract?rss=yes</link><description>Abstract: 
In order to assess the frequency of mutations in the known Alzheimer's disease causative genes in Turkish dementia patients we screened amyloid precursor protein (APP), PSEN1 and PSEN2 for mutations in a cohort of 98 Turkish dementia families. Six families were found to carry PSEN1 mutations (p.H163R, p.P264L, and p.H214Y) or variants suggested to cause the disease (p.L134R, p.L262V, and p.A396T). In 4 other families, previously reported PSEN2 variants were identified (p.R62H, p.R71W, p.M174V (n = 2), and p.S130L). The phenotype of the carriers varied from rapid progressing Alzheimer's disease to frontotemporal dementia, with spasticity and seizures also observed. Here we report a frequency of 11.2% of mutations and variants in the known Alzheimer disease genes in the dementia cohort studied and 24% in the early onset subgroup of patients, suggesting that mutations in these genes are not uncommon in Turkey and are associated with various phenotypes. We thus believe that genetic analysis should become a standardized diagnostic implement, not only for the identification of the genetic disease, but also for appropriate genetic counseling.
</description><dc:title>Identification of PSEN1 and PSEN2 gene mutations and variants in Turkish dementia patients - Corrected Proof</dc:title><dc:creator>Ebba Lohmann, Rita J. Guerreiro, Nihan Erginel-Unaltuna, Nicole Gurunlian, Basar Bilgic, Hakan Gurvit, Hasmet A. Hanagasi, Nga Luu, Murat Emre, Andrew Singleton</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.020</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-16</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-16</prism:publicationDate><prism:section>ORIGINAL ARTICLES</prism:section></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001984/abstract?rss=yes"><title>Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001984/abstract?rss=yes</link><description>Abstract: 
This study modeled predementia Alzheimer's disease clinical trials. Longitudinal data from cognitively normal (CN) and mild cognitive impairment (MCI) participants in the Alzheimer's Disease Neuroimaging Initiative were used to calculate sample size requirements for trials using outcome measures, including the Clinical Dementia Rating scale sum of boxes, Mini-Mental State Examination, Alzheimer's Disease Assessment Scale-cognitive subscale with and without delayed recall, and the Rey Auditory Verbal Learning Task. We examined the impact on sample sizes of enrichment for genetic and biomarker criteria, including cerebrospinal fluid protein and neuroimaging analyses. We observed little cognitive decline in the CN population at 36 months, regardless of the enrichment strategy. Nonetheless, in CN subjects, using Rey Auditory Verbal Learning Task total as an outcome at 36 months required the fewest subjects across enrichment strategies, with apolipoprotein E genotype ε4 carrier status requiring the fewest (n = 499 per arm to demonstrate a 25% reduction in disease progression). In MCI, enrichment reduced the required sample sizes for trials, relative to estimates based on all subjects. For MCI, the Clinical Dementia Rating scale sum of boxes consistently required the smallest sample sizes. We conclude that predementia clinical trial conduct in Alzheimer's disease is enhanced by the use of biomarker inclusion criteria.
</description><dc:title>Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative - Corrected Proof</dc:title><dc:creator>Joshua D. Grill, Lijie Di, Po H. Lu, Cathy Lee, John Ringman, Liana G. Apostolova, Nicole Chow, Omid Kohannim, Jeffrey L. Cummings, Paul M. Thompson, David Elashoff, Alzheimer's Disease Neuroimaging Initiative</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.03.006</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-16</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-16</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS019745801200214X/abstract?rss=yes"><title>CGG-repeat expansion in FMR1 is not associated with amyotrophic lateral sclerosis - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS019745801200214X/abstract?rss=yes</link><description>Abstract: 
Recently, repeat expansions in several genes have been shown to cause or be associated with amyotrophic lateral sclerosis (ALS). It has been demonstrated that an intronic hexanucleotide repeat expansion in C9ORF72 is a major cause of both familial (approximately 40%) and sporadic (approximately 5%) ALS, as well as frontotemporal dementia (FTD). In addition, a CAG-repeat expansion in exon 1 of ATXN2, otherwise known to cause spinocerebellar ataxia type 2, has been identified as a major risk factor for sporadic ALS. Intermediate repeat expansions in the fragile X mental retardation 1 (FMR1) gene (55–200 repeats) are known to cause fragile X-associated premature ovarian insufficiency [(FX)POI; female carriers] or fragile X-associated tremor/ataxia syndrome (FXTAS; male carriers) by CGG-mediated RNA toxicity. The present investigation involves screening FMR1 repeat length in 742 sporadic ALS patients and 792 matched controls. Our conclusion is that FMR1 repeat expansions are not associated with ALS.
</description><dc:title>CGG-repeat expansion in FMR1 is not associated with amyotrophic lateral sclerosis - Corrected Proof</dc:title><dc:creator>Ewout J.N. Groen, Wouter van Rheenen, Max Koppers, Perry T.C. van Doormaal, Lotte Vlam, Frank P. Diekstra, Dennis Dooijes, R. Jeroen Pasterkamp, Leonard H. van den Berg, Jan H. Veldink</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.03.007</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-16</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-16</prism:publicationDate><prism:section>NEGATIVE RESULTS</prism:section></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001807/abstract?rss=yes"><title>Age-related appearance of dendritic inclusions in catecholaminergic brainstem neurons - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001807/abstract?rss=yes</link><description>Abstract: 
We identified p62-immunoreactive inclusions in dendrites of catecholaminergic brainstem projection neurons using antibodies against p62, ubiquitin, α-synuclein, hyperphosphorylated tau, and tyrosine hydroxylase in 100-μm sections through the brainstem dorsal vagal area, locus coeruleus, and substantia nigra of 149 autopsy cases staged for intraneuronal Alzheimer's and Parkinson's disease-associated lesions. The inclusions resembled Marinesco bodies within cell nuclei of catecholaminergic neurons as well as the dot-like structures previously described by Dickson in specific neuropil areas in humans. The p62-positive inclusions were confined to dendrites of catecholaminergic neurons, lacked neuromelanin granules, and were tau- and α-synuclein-negative. Their immunoreactivity for ubiquitin varied and their prevalence significantly increased with advancing age. The presence or absence of Alzheimer's and/or Parkinson's disease-associated pathology did not influence their existence. There was a strong association between the presence of p62-positive inclusions and Marinesco bodies (p &lt; 0.0001). Our results reveal a hitherto unknown alteration within specific neuronal types of the human brainstem that may be independent of the sequestosome-ubiquitin-proteasomal pathway and unrelated to proteinaceous aggregate-formation of neurodegenerative diseases.
</description><dc:title>Age-related appearance of dendritic inclusions in catecholaminergic brainstem neurons - Corrected Proof</dc:title><dc:creator>Heiko Braak, Dietmar Rudolf Thal, Jakob Matschke, Estifanos Ghebremedhin, Kelly Del Tredici</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.031</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-13</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-13</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001819/abstract?rss=yes"><title>O-linked β-N-acetylglucosaminidase inhibitor attenuates β-amyloid plaque and rescues memory impairment - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001819/abstract?rss=yes</link><description>Abstract: 
Deposition of β-amyloid (Aβ) as senile plaques and disrupted glucose metabolism are two main characteristics of Alzheimer's disease (AD). It is unknown, however, how these two processes are related in AD. Here we examined the relationship between O-GlcNAcylation, which is a glucose level-dependent post-translational modification that adds O-linked β-N-acetylglucosamine (O-GlcNAc) to proteins, and Aβ production in a mouse model of AD carrying 5XFAD genes. We found that 1,2-dideoxy-2′-propyl-α-d-glucopyranoso-[2,1-d]-Δ2′-thiazoline (NButGT), a specific inhibitor of O-GlcNAcase, reduces Aβ production by lowering γ-secretase activity both in vitro and in vivo. We also found that O-GlcNAcylation takes place at the S708 residue of nicastrin, which is a component of γ-secretase. Moreover, NButGT attenuated the accumulation of Aβ, neuroinflammation, and memory impairment in the 5XFAD mice. This is the first study to show the relationship between Aβ generation and O-GlcNAcylation in vivo. These results suggest that O-GlcNAcylation may be a suitable therapeutic target for the treatment of AD.
</description><dc:title>O-linked β-N-acetylglucosaminidase inhibitor attenuates β-amyloid plaque and rescues memory impairment - Corrected Proof</dc:title><dc:creator>Chaeyoung Kim, Dong Woo Nam, Sang Yoon Park, Hyundong Song, Hyun Seok Hong, Jung Hyun Boo, Eun Sun Jung, Yoonhee Kim, Ju Yuel Baek, Kwan Soo Kim, Jin Won Cho, Inhee Mook-Jung</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.03.001</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-13</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-13</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001820/abstract?rss=yes"><title>Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001820/abstract?rss=yes</link><description>Abstract: 
This study examines the relationship between fibrillar beta-amyloid (Aβ) deposition and reduced glucose metabolism, a proxy for neuronal dysfunction, in cognitively normal (NL) individuals with a parent affected by late-onset Alzheimer's disease (AD). Forty-seven 40–80-year-old NL received positron emission tomography (PET) with C-Pittsburgh compound B (PiB) and 18F-fluoro-2-deoxy-d-glucose (FDG). These included 19 NL with a maternal history (MH), 12 NL with a paternal history (PH), and 16 NL with negative family history of AD (NH). Automated regions of interest, statistical parametric mapping, voxel-wise intermodality correlations, and logistic regressions were used to examine cerebral-to-cerebellar PiB and FDG standardized uptake value ratios across groups. The MH group showed higher PiB retention and lower metabolism in AD regions compared with NH and PH, which were negatively correlated in posterior cingulate, frontal, and parieto-temporal regions (Pearson r ≤ −0.57, p ≤ 0.05). No correlations were observed in NH and PH. The combination of Aβ deposition and metabolism yielded accuracy ≥ 69% for MH vs. NH and ≥ 71% for MH vs. PH, with relative risk = 1.9–5.1 (p values &lt; 0.005). NL individuals with AD-affected mothers show co-occurring Aβ increases and hypometabolism in AD-vulnerable regions, suggesting an increased risk for AD.
</description><dc:title>Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents - Corrected Proof</dc:title><dc:creator>Lisa Mosconi, Juha O. Rinne, Wai H. Tsui, John Murray, Yi Li, Lidia Glodzik, Pauline McHugh, Schantel Williams, Megan Cummings, Elizabeth Pirraglia, Stanley J. Goldsmith, Shankar Vallabhajosula, Noora Scheinin, Tapio Viljanen, Kjell Någren, Mony J. de Leon</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.03.002</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-13</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-13</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001959/abstract?rss=yes"><title>How can elderly apolipoprotein E ε4 carriers remain free from dementia? - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001959/abstract?rss=yes</link><description>Abstract: 
Apolipoprotein E (APOE) ε4 is a major risk factor for Alzheimer's disease (AD) and dementia, but not all ε4 carriers develop dementia. We sought to identify factors that may play a role in modifying the risk of dementia due to ε4. A cognitively intact cohort (n = 932, age ≥ 75) was followed for 9 years to detect incident dementia cases. At baseline, information on education, leisure activities, and vascular risk factors was collected, and APOE was genotyped. During the follow-up, 324 subjects developed dementia, including 247 AD cases. The hazard ratio (HR, 95% confidence interval [95% CI]) of dementia related to the ε4 was 1.39 (1.11–1.76), while the risk was reduced when ε4 carriers had high education, no vascular risk factors, or high score of leisure activities. Among ε4 carriers, the multiadjusted HRs of dementia that were associated with high education, high level of leisure activities, and absence of vascular risk factors were 0.59 (0.40–0.87), 0.49 (0.29–0.85), and 0.61 (0.41–0.90), respectively. The ε4 carriers with these factors had about 1.2 years delayed time to dementia onset compared with those without these factors. High education, active leisure activities, or maintaining vascular health seems to reduce the risk of dementia related to APOE ε4. The ε4 carriers with these characteristics appear to have similar dementia-free survival time to non-ε4 carriers.
</description><dc:title>How can elderly apolipoprotein E ε4 carriers remain free from dementia? - Corrected Proof</dc:title><dc:creator>Camilla Ferrari, Wei-Li Xu, Hui-Xin Wang, Bengt Winblad, Sandro Sorbi, Chengxuan Qiu, Laura Fratiglioni</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.03.003</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-13</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-13</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001972/abstract?rss=yes"><title>Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001972/abstract?rss=yes</link><description>Abstract: 
A hexanucleotide repeat expansion in chromosome 9 open reading frame 72 (C9ORF72) gene has recently been described as a cause of familial and sporadic frontotemporal lobar degeneration. The aim of this study was to assess whether plasma progranulin (GRN) levels could be modulated by the presence of this repeat expansion. Sixty-five patients diagnosed with frontotemporal dementia and 10 family members with familial aggregation of disease were screened for the presence of the hexanucleotide repeat expansion in C9ORF72 gene, using a repeat-primed polymerase chain reaction method. Plasma GRN levels were measured in all subjects through enzyme-linked immunosorbent assay. Seven individuals with the repeat expansion were identified. No differences were found between C9ORF72 repeat expansion carriers and noncarriers (116.4 ± 21 ng/mL and 131.7 ± 36 ng/mL, respectively, p = 0.3). Analysis of family members did not disclose any difference in plasma GRN levels between carriers and noncarriers. In conclusion, plasma GRN levels are not influenced by the hexanucleotide repeat expansion in C9ORF72 gene, and therefore, cannot be used as a reliable biomarker to detect mutation carriers.
</description><dc:title>Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia - Corrected Proof</dc:title><dc:creator>Oriol Dols-Icardo, Marc Suárez-Calvet, Isabel Hernández, Guillermo Amer, Sofía Antón-Aguirre, Daniel Alcolea, Juan Fortea, Mercè Boada, Lluís Tárraga, Rafael Blesa, Alberto Lleó, Jordi Clarimón</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.03.005</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-13</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-13</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012002163/abstract?rss=yes"><title>Frontal asymmetry in behavioral variant frontotemporal dementia: clinicoimaging and pathogenetic correlates - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012002163/abstract?rss=yes</link><description>Abstract: 
We aimed to assess associations between clinical, imaging, pathologic, and genetic features and frontal lobe asymmetry in behavioral variant frontotemporal dementia (bvFTD). Volumes of the left and right dorsolateral, medial, and orbital frontal lobes were measured in 80 bvFTD subjects and subjects were classified into 3 groups according to the degree of asymmetry (asymmetric left, asymmetric right, symmetric) using cluster analysis. The majority of subjects were symmetric (65%), with 20% asymmetric left and 15% asymmetric right. There were no clinical differences across groups, although there was a trend for greater behavioral dyscontrol in right asymmetric compared with left asymmetric subjects. More widespread atrophy involving the parietal lobe was observed in the symmetric group. Genetic features differed across groups with symmetric frontal lobes associated with C9ORF72 and tau mutations, while asymmetric frontal lobes were associated with progranulin mutations. These findings therefore suggest that neuroanatomical patterns of frontal lobe atrophy in bvFTD are influenced by specific gene mutations.
</description><dc:title>Frontal asymmetry in behavioral variant frontotemporal dementia: clinicoimaging and pathogenetic correlates - Corrected Proof</dc:title><dc:creator>Jennifer L. Whitwell, Jia Xu, Jay Mandrekar, Bradley F. Boeve, David S. Knopman, Joseph E. Parisi, Matthew L. Senjem, Dennis W. Dickson, Ronald C. Petersen, Rosa Rademakers, Clifford R. Jack, Keith A. Josephs</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.03.009</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-13</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-13</prism:publicationDate><prism:section>BRIEF COMMUNICATION</prism:section></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001789/abstract?rss=yes"><title>Cognitive decline in Parkinson's disease is associated with slowing of resting-state brain activity: a longitudinal study - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001789/abstract?rss=yes</link><description>Abstract: 
The pathophysiological mechanisms of Parkinson's disease (PD)-related dementia (PDD) are still poorly understood. Previous studies using electroencephalography (EEG) and magnetoencephalography (MEG) have demonstrated widespread slowing of oscillatory brain activity as a neurophysiological characteristic of PD-related dementia. Here, we use MEG to longitudinally study early changes in oscillatory brain activity in initially nondemented PD patients that may be associated with cognitive decline. Using a longitudinal design, resting-state MEG recordings were performed twice at an approximate 4-year interval in 14 healthy controls and 49 PD patients. Changes in peak frequency and in relative spectral power for 10 brain regions were analyzed in relation to clinical measures of cognitive and motor function. In contrast to healthy controls, PD patients showed a slowing of the dominant peak frequency. Furthermore, analysis per frequency band revealed an increase in theta power over time, along with decreases in alpha1 and alpha2 power. In PD patients, decreasing cognitive performance was associated with increases in delta and theta power, as well as decreases in alpha1, alpha2, and gamma power, whereas increasing motor impairment was associated with a theta power increase only. The present longitudinal study revealed widespread progressive slowing of oscillatory brain activity in initially nondemented PD patients, independent of aging effects. The slowing of oscillatory brain activity strongly correlated with cognitive decline and therefore holds promise as an early marker for the development of dementia in PD.
</description><dc:title>Cognitive decline in Parkinson's disease is associated with slowing of resting-state brain activity: a longitudinal study - Corrected Proof</dc:title><dc:creator>Kim T.E. Olde Dubbelink, Diederick Stoffers, Jan Berend Deijen, Jos W.R. Twisk, Cornelis J. Stam, Henk W. Berendse</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.029</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-12</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-12</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001649/abstract?rss=yes"><title>Familial Lund frontotemporal dementia caused by C9ORF72 hexanucleotide expansion - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001649/abstract?rss=yes</link><description>Abstract: 
Frontotemporal dementia (FTD) as an important clinical entity was rediscovered in Lund and Manchester in the early 1990s. Here we show that the large Lund pedigree with behavioral variant of frontotemporal dementia previously described with this disorder has an expansion in the recently described C9ORF72 locus on chromosome 9.
</description><dc:title>Familial Lund frontotemporal dementia caused by C9ORF72 hexanucleotide expansion - Corrected Proof</dc:title><dc:creator>Elisabet Englund, Lars Gustafson, Ulla Passant, Elisa Majounie, Alan E. Renton, Bryan J. Traynor, Jonathan D. Rohrer, Kin Mok, John Hardy</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.019</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-09</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-09</prism:publicationDate><prism:section>BRIEF COMMUNICATION</prism:section></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001790/abstract?rss=yes"><title>Serum oxidized low-density lipoprotein level and risk of cognitive impairment in older women - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001790/abstract?rss=yes</link><description>Abstract: 
We investigated the association between serum level of oxidized low-density lipoprotein (oxLDL) and risk of cognitive impairment (dementia or mild cognitive impairment) among 572 nondemented community-dwelling women from a prospective cohort study of aging. After 5 years of follow-up, 228 (39.9%) developed cognitive impairment; and this did not differ by tertile of baseline oxLDL level (highest compared with lowest tertile 38.2% vs. 39.5%; odds ratio, 0.90; 95% confidence interval, 0.63–1.43). Multivariate adjustment produced similar results (odds ratio, 0.91; 95% confidence interval, 0.60–1.39). These findings suggest that increased levels of serum oxLDL are not associated with a greater risk of incident cognitive impairment in older women.
</description><dc:title>Serum oxidized low-density lipoprotein level and risk of cognitive impairment in older women - Corrected Proof</dc:title><dc:creator>Alain Koyama, Katie Stone, Kristine Yaffe</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.030</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-09</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-09</prism:publicationDate><prism:section>NEGATIVE RESULTS</prism:section></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001674/abstract?rss=yes"><title>Cholesteryl Ester Transfer Protein (CETP) genotype and cognitive function in persons aged 35 years or older - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001674/abstract?rss=yes</link><description>Abstract: 
Common polymorphisms of the Cholestryl Ester Transfer Protein (CETP) gene may predict lower risk of cognitive decline. We investigated the association of cognitive function with CETP genotype in a population-based cohort of 4135 persons aged 35–82 years. Cognitive function was measured with the Ruff Figural Fluency Test (RFFT; worst score, 0 points; best score, 175 points) and CETP I405V and Taq1B genotypes were determined by polymerase chain reaction. RFFT score was not associated with I405V genotype in persons aged 35–64 years. Remarkably, beyond age 65, homozygous valine carriers had higher RFFT scores than heterozygous carriers and noncarriers: RFFT (SD), 52 (21), 49 (18), and 47 (17) points, respectively (p = 0.005). There also was a statistically significant interaction between I405V genotype and age. Beyond age 65, the difference between homozygous valine carriers and noncarriers increased by 0.11 point per year (p = 0.005). RFFT score was not associated with Taq1B genotype. In conclusion, CETP I405V valine homozygosity was associated with better cognitive function in persons aged 65 years or older.
</description><dc:title>Cholesteryl Ester Transfer Protein (CETP) genotype and cognitive function in persons aged 35 years or older - Corrected Proof</dc:title><dc:creator>Gerbrand J. Izaks, Aafke M. van der Knaap, Ron T. Gansevoort, Gerjan Navis, Joris P.J. Slaets, Robin P.F. Dullaart</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.022</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-05</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-05</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS019745801200173X/abstract?rss=yes"><title>Presenilin mediates neuroprotective functions of ephrinB and brain-derived neurotrophic factor and regulates ligand-induced internalization and metabolism of EphB2 and TrkB receptors - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS019745801200173X/abstract?rss=yes</link><description>Abstract: 
Activation of EphB receptors by ephrinB (efnB) ligands on neuronal cell surface regulates important functions, including neurite outgrowth, axonal guidance, and synaptic plasticity. Here, we show that efnB rescues primary cortical neuronal cultures from necrotic cell death induced by glutamate excitotoxicity and that this function depends on EphB receptors. Importantly, the neuroprotective function of the efnB/EphB system depends on presenilin 1 (PS1), a protein that plays crucial roles in Alzheimer's disease (AD) neurodegeneration. Furthermore, absence of one PS1 allele results in significantly decreased neuroprotection, indicating that both PS1 alleles are necessary for full expression of the neuroprotective activity of the efnB/EphB system. We also show that the ability of brain-derived neurotrophic factor (BDNF) to protect neuronal cultures from glutamate-induced cell death depends on PS1. Neuroprotective functions of both efnB and BDNF, however, were independent of γ-secretase activity. Absence of PS1 decreases cell surface expression of neuronal TrkB and EphB2 without affecting total cellular levels of the receptors. Furthermore, PS1-knockout neurons show defective ligand-dependent internalization and decreased ligand-induced degradation of TrkB and Eph receptors. Our data show that PS1 mediates the neuroprotective activities of efnB and BDNF against excitotoxicity and regulates surface expression and ligand-induced metabolism of their cognate receptors. Together, our observations indicate that PS1 promotes neuronal survival by regulating neuroprotective functions of ligand-receptor systems.
</description><dc:title>Presenilin mediates neuroprotective functions of ephrinB and brain-derived neurotrophic factor and regulates ligand-induced internalization and metabolism of EphB2 and TrkB receptors - Corrected Proof</dc:title><dc:creator>Gael Barthet, Julie Dunys, Zhiping Shao, Zhao Xuan, Yimin Ren, Jindong Xu, Nicolas Arbez, Gweltas Mauger, Julien Bruban, Anastasios Georgakopoulos, Junichi Shioi, Nikolaos K. Robakis</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.024</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-05</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-05</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001753/abstract?rss=yes"><title>Serum leptin and cognitive function in people with Type 2 diabetes - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001753/abstract?rss=yes</link><description>Abstract: 
People with obesity and type 2 diabetes are at increased risk of cognitive impairment. We aimed to investigate the association of leptin with cognitive abilities in an elderly population with type 2 diabetes. We performed a cross-sectional study of 1057 men and women aged 60–75 years with type 2 diabetes living in Lothian (Scotland). A cognitive battery was administered. Prior intelligence was estimated from vocabulary testing and adjustment for scores on this test was used to estimate lifetime cognitive change. Relationships between fasting morning leptin levels and cognitive ability and estimated cognitive change were tested. Higher leptin levels were associated with significantly poorer estimated overall cognitive decline, and poorer performance in 2 cognitive domains assessing mental flexibility and executive function, only amongst men (p &lt; 0.05). High morning leptin levels in elderly men with type 2 diabetes are associated with estimated age-related cognitive change.
</description><dc:title>Serum leptin and cognitive function in people with Type 2 diabetes - Corrected Proof</dc:title><dc:creator>Javier Labad, Jacqueline F. Price, Mark W.J. Strachan, Ian J. Deary, Jonathan R. Seckl, Naveed Sattar, Rebecca M. Reynolds, Edinburgh Type 2 Diabetes Study (ET2DS) Investigators</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.026</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-05</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-05</prism:publicationDate><prism:section>BRIEF COMMUNICATION</prism:section></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001765/abstract?rss=yes"><title>Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001765/abstract?rss=yes</link><description>Abstract: 
Substantial resources and effort have been invested into the development of therapeutic agents for Alzheimer's disease (AD) with mixed and limited success. Research into the etiology of AD with animal models mimicking aspects of the disorder has substantially contributed to the advancement of potential therapies. Although these models have shown utility in testing novel therapeutic candidates, large variability still exists in terms of methodology and how the models are utilized. No model has yet predicted a successful disease-modifying therapy for AD. This report reviews several of the widely accepted transgenic and nontransgenic animal models of AD, highlighting the pathological and behavioral characteristics of each. Methodological considerations for conducting preclinical animal research are discussed, such as which behavioral tasks and histological markers may be associated with the greatest insight into therapeutic benefit. An overview of previous and current therapeutic interventions being investigated in AD models is presented, with an emphasis on factors that may have contributed to failure in past clinical trials. Finally, we propose a multitiered approach for investigating candidate therapies for AD that may reduce the likelihood of inappropriate conclusions from models and failed trials in humans.
</description><dc:title>Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications - Corrected Proof</dc:title><dc:creator>Jonathan J. Sabbagh, Jefferson W. Kinney, Jeffrey L. Cummings</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.027</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-04-02</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-04-02</prism:publicationDate><prism:section>REVIEW</prism:section></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001546/abstract?rss=yes"><title>Mutant FUS induces endoplasmic reticulum stress in amyotrophic lateral sclerosis and interacts with protein disulfide-isomerase - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001546/abstract?rss=yes</link><description>Abstract: 
Mutations in the gene encoding fused in sarcoma (FUS) are linked to amyotrophic lateral sclerosis (ALS), but the mechanisms by which these mutants trigger neurodegeneration remain unknown. Endoplasmic reticulum (ER) stress is increasingly recognized as an important and early pathway to motor neuron death in ALS. FUS is normally located in the nucleus but in ALS, FUS redistributes to the cytoplasm and forms inclusions. In this study, we investigated whether FUS induces ER stress in a motor neuron like cell line (NSC-34). We demonstrate that ER stress is triggered in cells expressing mutant FUS, and this is closely associated with redistribution of mutant FUS to the cytoplasm. Mutant FUS also colocalized with protein disulfide-isomerase (PDI), an important ER chaperone, in NSC-34 cells and PDI was colocalized with FUS inclusions in human ALS lumbar spinal cords, in both sporadic ALS and mutant FUS-linked familial ALS tissues. These findings implicate ER stress in the pathophysiology of FUS, and provide evidence for common pathogenic pathways in ALS linked to the ER.
</description><dc:title>Mutant FUS induces endoplasmic reticulum stress in amyotrophic lateral sclerosis and interacts with protein disulfide-isomerase - Corrected Proof</dc:title><dc:creator>Manal A. Farg, Kai Y. Soo, Adam K. Walker, Hong Pham, Jacqueline Orian, Malcolm K. Horne, Sadaf T. Warraich, Kelly L. Williams, Ian P. Blair, Julie D. Atkin</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.009</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-03-30</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-03-30</prism:publicationDate><prism:section>ORIGINAL ARTICLES</prism:section></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001613/abstract?rss=yes"><title>Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001613/abstract?rss=yes</link><description>Abstract: 
The accumulation of β-amyloid (Aβ) peptide derived from abnormal processing of amyloid precursor protein (APP) is a common pathological hallmark of Alzheimer's disease (AD) brains. In this study, we evaluated the therapeutic effect of berberine (BBR) extracted from Coptis chinensis Franch, a Chinese medicinal herb, on the neuropathology and cognitive impairment in TgCRND8 mice, a well established transgenic mouse model of AD. Two-month-old TgCRND8 mice received a low (25 mg/kg per day) or a high dose of BBR (100 mg/kg per day) by oral gavage until 6 months old. BBR treatment significantly ameliorated learning deficits, long-term spatial memory retention, as well as plaque load compared with vehicle control treatment. In addition, enzyme-linked immunosorbent assay (ELISA) measurement showed that there was a profound reduction in levels of detergent-soluble and -insoluble β-amyloid in brain homogenates of BBR-treated mice. Glycogen synthase kinase (GSK)3, a major kinase involved in APP and tau phosphorylation, was significantly inhibited by BBR treatment. We also found that BBR significantly decreased the levels of C-terminal fragments of APP and the hyperphosphorylation of APP and tau via the Akt/glycogen synthase kinase 3 signaling pathway in N2a mouse neuroblastoma cells stably expressing human Swedish mutant APP695 (N2a-SwedAPP). Our results suggest that BBR provides neuroprotective effects in TgCRND8 mice through regulating APP processing and that further investigation of the BBR for therapeutic use in treating AD is warranted.
</description><dc:title>Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model - Corrected Proof</dc:title><dc:creator>Siva Sundara Kumar Durairajan, Liang-Feng Liu, Jia-Hong Lu, Lei-Lei Chen, Qiuju Yuan, Sookja K. Chung, Ling Huang, Xing-Shu Li, Jian-Dong Huang, Min Li</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.016</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-03-29</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-03-29</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001625/abstract?rss=yes"><title>Screening for C9ORF72 repeat expansion in FTLD - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001625/abstract?rss=yes</link><description>Abstract: 
In the present study we aimed to determine the prevalence of C9ORF72 GGGGCC hexanucleotide expansion in our cohort of 53 frontotemporal lobar degeneration (FTLD) patients and 174 neurologically normal controls. We identified the hexanucleotide repeat, in the pathogenic range, in 4 (2 bv-frontotemporal dementia (FTD) and 2 FTD-amyotrophic lateral sclerosis [ALS]) out of 53 patients and 1 neurologically normal control. Interestingly, 2 of the C9ORF72 expansion carriers also carried 2 novel missense mutations in GRN (Y294C) and in PSEN-2(I146V). Further, 1 of the C9ORF72 expansion carriers, for whom pathology was available, showed amyloid plaques and tangles in addition to TAR (trans-activation response) DNA-binding protein (TDP)-43 pathology. In summary, our findings suggest that the hexanucleotide expansion is probably associated with ALS, FTD, or FTD-ALS and occasional comorbid conditions such as Alzheimer's disease. These findings are novel and need to be cautiously interpreted and most importantly replicated in larger numbers of samples.
</description><dc:title>Screening for C9ORF72 repeat expansion in FTLD - Corrected Proof</dc:title><dc:creator>Raffaele Ferrari, Kin Mok, Jorge H. Moreno, Stephanie Cosentino, Jill Goldman, Pietro Pietrini, Richard Mayeux, Michael C. Tierney, Dimitrios Kapogiannis, Gregory A. Jicha, Jill R. Murrell, Bernardino Ghetti, Eric M. Wassermann, Jordan Grafman, John Hardy, Edward D. Huey, Parastoo Momeni</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.017</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-03-29</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-03-29</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001741/abstract?rss=yes"><title>Age-related frontoparietal changes during the control of bottom-up and top-down attention: an ERP study - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001741/abstract?rss=yes</link><description>Abstract: 
We investigated age-related changes in frontal and parietal scalp event-related potential (ERP) activity during bottom-up and top-down attention. Younger and older participants were presented with arrays constructed to induce either automatic “pop-out” (bottom-up) or effortful “search” (top-down) behavior. Reaction times (RTs) increased and accuracy decreased with age, with a greater age-related decline in accuracy for the search than for the pop-out condition. The latency of the P300 elicited by the visual search array was shorter in both conditions in the younger than in the older adults. Pop-out target detection was associated with greater activity at parietal than at prefrontal locations in younger participants and with a more equipotential prefrontal-parietal distribution in older adults. Search target detection was associated with greater activity at prefrontal than at parietal locations in older relative to younger participants. Thus, aging was associated with a more prefrontal P300 scalp distribution during the control of bottom-up and top-down attention. Early latency extrastriate potentials were enhanced and N2-posterior-contralateral (N2pc) was reduced in the older group, supporting the idea that the frontal enhancements may be due to a compensation for disinhibition and distraction in the older adults. Taken together these findings provide evidence that younger and older adults recruit different frontal-parietal networks during top-down and bottom-up attention, with older adults increasing their recruitment of a more frontally distributed network in both of these types of attention. This work is in accord with previous neuroimaging findings suggesting that older adults recruit more frontal activity in the service of a variety of tasks than younger adults.
</description><dc:title>Age-related frontoparietal changes during the control of bottom-up and top-down attention: an ERP study - Corrected Proof</dc:title><dc:creator>Ling Li, Caterina Gratton, Monica Fabiani, Robert T. Knight</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.025</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-03-29</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-03-29</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001777/abstract?rss=yes"><title>Phospholipase A2: The key to reversing long-term memory impairment in a gastropod model of aging - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001777/abstract?rss=yes</link><description>Abstract: 
Memory failure associated with changes in neuronal circuit functions rather than cell death is a common feature of normal aging in diverse animal species. The (neuro)biological foundations of this phenomenon are not well understood although oxidative stress, particularly in the guise of lipid peroxidation, is suspected to play a key role. Using an invertebrate model system of age-associated memory impairment that supports direct correlation between behavioral deficits and changes in the underlying neural substrate, we show that inhibition of phospholipase A2 (PLA2) abolishes both long-term memory (LTM) and neural defects observed in senescent subjects and subjects exposed to experimental oxidative stress. Using a combination of behavioral assessments and electrophysiological techniques, we provide evidence for a close link between lipid peroxidation, provocation of phospholipase A2-dependent free fatty acid release, decline of neuronal excitability, and age-related long-term memory impairments. This supports the view that these processes suspend rather than irreversibly extinguish the aging nervous system's intrinsic capacity for plasticity.
</description><dc:title>Phospholipase A2: The key to reversing long-term memory impairment in a gastropod model of aging - Corrected Proof</dc:title><dc:creator>Shawn N. Watson, Natasha Wright, Petra M. Hermann, Willem C. Wildering</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.028</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-03-29</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-03-29</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001327/abstract?rss=yes"><title>Extracellular signal-regulated kinase is involved in alpha-synuclein-induced mitochondrial dynamic disorders by regulating dynamin-like protein 1 - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001327/abstract?rss=yes</link><description>Abstract: 
Compounding evidence suggests that alpha-synuclein (SNCA) plays an important role in the pathogenesis of Parkinson's disease (PD) by inducing neurotoxicity. Mitochondria are highly dynamic organelles that undergo fusion and fission processes, the imbalance of which has been viewed as a key trigger for PD. However, the underlying relationship between SNCA and mitochondrial dynamics remains unclear. This study demonstrated that SNCA overexpression not only altered mitochondrial morphology, but also significantly increased the translocation of mitochondrial fission protein dynamin-like protein 1 (DLP1). To further investigate the mechanism of SNCA's effect on mitochondrial dynamics, the proteomic technique, stable isotope labeling of amino acid in cell cultures (SILAC), was used. The extracellular signal-regulated kinase (ERK) was confirmed to be involved in the regulation of DLP1 and SNCA-mediated neurotoxicity. Finally, additional results demonstrated that SNCA inducing both mitochondrial dynamic disorders and neurotoxicity could be ameliorated by curcumin through ERK inhibition, which implied that the agent could be used to prevent and treat PD in the future.
</description><dc:title>Extracellular signal-regulated kinase is involved in alpha-synuclein-induced mitochondrial dynamic disorders by regulating dynamin-like protein 1 - Corrected Proof</dc:title><dc:creator>Ya-Xing Gui, Xin-Yi Wang, Wen-Yan Kang, Ying-Jie Zhang, Yu Zhang, Yong Zhou, Thomas J. Quinn, Jun Liu, Sheng-Di Chen</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.001</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-03-26</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-03-26</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001510/abstract?rss=yes"><title>Effect of aging on 5-hydroxymethylcytosine in brain mitochondria - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001510/abstract?rss=yes</link><description>Abstract: 
Nuclear epigenetics of the mammalian brain is modified during aging. Little is known about epigenetic modifications of mitochondrial DNA (mtDNA). We analyzed brain samples of 4- and 24-month-old mice and found that aging decreased mtDNA 5-hydroxymethylcytosine (5hmC) but not 5-methylcytosine (5mC) levels in the frontal cortex but not the cerebellum. Transcript levels of selected mtDNA-encoded genes increased during aging in the frontal cortex only. Aging affected the expression of enzymes involved in 5-methylcytosine and 5-hydroxymethylcytosine synthesis (mitochondrial DNA methyltransferase 1 [mtDNMT1] and ten-eleven-translocation [TET]1-TET3, respectively). In the frontal cortex, aging decreased mtDNMT1 messenger RNA (mRNA) levels without affecting TET1-TET3 mRNAs. In the cerebellum, TET2 and TET3 mRNA content was increased but mtDNMT1 mRNA was unaffected. Using Western immunoblotting of samples from primary neuronal cultures, we found TET immunoreactivity in the mitochondrial fraction. At the single cell level, TET immunoreactivity was detected in the nucleus and in the perinuclear/intraneurite areas where it frequently colocalized with a mitochondrial marker. Our results demonstrated the presence and susceptibility to aging of mitochondrial epigenetic mechanisms in the mammalian brain.
</description><dc:title>Effect of aging on 5-hydroxymethylcytosine in brain mitochondria - Corrected Proof</dc:title><dc:creator>Svetlana Dzitoyeva, Hu Chen, Hari Manev</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.006</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-03-26</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-03-26</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001595/abstract?rss=yes"><title>Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS) - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001595/abstract?rss=yes</link><description>Abstract: 
Genetics plays a crucial role in human aging with up to 30% of those living to the mid-80s being determined by genetic variation. Survival to older ages likely entails an even greater genetic contribution. There is increasing evidence that genes implicated in age-related diseases, such as cancer and neuronal disease, play a role in affecting human life span. We have selected the 10 most promising late-onset Alzheimer's disease (LOAD) susceptibility genes identified through several recent large genome-wide association studies (GWAS). These 10 LOAD genes (APOE, CLU, PICALM, CR1, BIN1, ABCA7, MS4A6A, CD33, CD2AP, and EPHA1) have been tested for association with human aging in our dataset (1385 samples with documented age at death [AAD], age range: 58–108 years; mean age at death: 80.2) using the most significant single nucleotide polymorphisms (SNPs) found in the previous studies. Apart from the APOE locus (rs2075650) which showed compelling evidence of association with risk on human life span (p = 5.27 × 10−4), none of the other LOAD gene loci demonstrated significant evidence of association. In addition to examining the known LOAD genes, we carried out analyses using age at death as a quantitative trait. No genome-wide significant SNPs were discovered. Increasing sample size and statistical power will be imperative to detect genuine aging-associated variants in the future. In this report, we also discuss issues relating to the analysis of genome-wide association studies data from different centers and the bioinformatic approach required to distinguish spurious genome-wide significant signals from real SNP associations.
</description><dc:title>Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS) - Corrected Proof</dc:title><dc:creator>Hui Shi, Olivia Belbin, Christopher Medway, Kristelle Brown, Noor Kalsheker, Minerva Carrasquillo, Petroula Proitsi, John Powell, Simon Lovestone, Alison Goate, Steven Younkin, Peter Passmore, Kevin Morgan, Genetic and Environmental Risk for Alzheimer's Disease (GERAD1) Consortium, Alzheimer's Research UK (ARUK) Consortium</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.014</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-03-26</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-03-26</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001637/abstract?rss=yes"><title>Reduced aging defects in estrogen receptive brainstem nuclei in the female hamster - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001637/abstract?rss=yes</link><description>Abstract: 
The nucleus pararetroambiguus (NPRA) and the commissural nucleus of the solitary tract (NTScom) show estrogen nuclear receptor-α immunoreactivity (nuclear ER-α-IR). Both cell groups are involved in estrous cycle related adaptations. We examined in normally cycling aged hamsters the occurrence/amount/frequency of age-related degenerative changes in NPRA and NTScom during estrus and diestrus. In 2640 electron microscopy photomicrographs plasticity reflected in the ratio of axon terminal surface/dendrite surface (t/d) was morphometrically analyzed. Medial tegmental field (mtf, nuclear ER-α-IR poor), served as control. In aged animals, irrespective of nuclear ER-α-IR+ or nuclear ER-α-IR− related cell groups, extensive diffuse degenerative structural aberrations were observed. The hormonal state had a strong influence on t/d ratios in NPRA and NTScom, but not in mtf. In NPRA and NTScom, diestrous hamsters had significantly smaller t/d ratios (NPRA, 0.750 ± 0.050; NTScom, 0.900 ± 0.039) than the estrous hamsters (NPRA, 1.083 ± 0.075; NTScom, 1.204 ± 0.076). Aging affected axodendritic ratios only in mtf (p &lt; 0.001). In conclusion: in the female hamster brain, estrous cycle-induced structural plasticity is preserved in NPRA and NTScom during aging despite the presence of diffuse age-related neurodegenerative changes.
</description><dc:title>Reduced aging defects in estrogen receptive brainstem nuclei in the female hamster - Corrected Proof</dc:title><dc:creator>Peter O. Gerrits, Rudie Kortekaas, Jan G. Veening, Henk de Weerd, Johannes J.L. van der Want</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.018</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-03-26</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-03-26</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001662/abstract?rss=yes"><title>High frequency of the expanded C9ORF72 hexanucleotide repeat in familial and sporadic Greek ALS patients - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001662/abstract?rss=yes</link><description>Abstract: 
An intronic expansion of a hexanucleotide GGGGCC repeat in the C9ORF72 gene has recently been shown to be an important cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) in familial and sporadic cases. The frequency has only been defined in a small number of populations where the highest sporadic rate was identified in Finland (21.1%) and the lowest in mainland Italy (4.1%). We examined the C9ORF72 expansion in a series of 146 Greek ALS cases, 10.95% (n = 16) of cases carried the pathological expansion defined as greater than 30 repeats. In the 10 familial ALS probands, 50% (n = 5) of them carried a pathologically large expansion. In the remaining 136 sporadic ALS cases, 11 were carriers (8.2%). None of the 228 Greek controls carried an expanded repeat. The phenotype of our cases was spinal (13/16) or bulbar (3/16) ALS, the familial cases were all spinal ALS and none of our cases had behavioral frontotemporal dementia. Expansions in the C9ORF72 gene therefore represent a common cause of ALS in Greece and this test will be diagnostically very important to implement in the Greek population. The frequency is higher than other populations with the exception of Finland and this may be due to Greece being a relatively isolated population.
</description><dc:title>High frequency of the expanded C9ORF72 hexanucleotide repeat in familial and sporadic Greek ALS patients - Corrected Proof</dc:title><dc:creator>Kin Y. Mok, Georgios Koutsis, Lucia V. Schottlaender, James Polke, Marios Panas, Henry Houlden</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.021</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-03-26</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-03-26</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001728/abstract?rss=yes"><title>Early cerebrovascular inflammation in a transgenic mouse model of Alzheimer's disease - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001728/abstract?rss=yes</link><description>Abstract: 
Amyloid plaques associated with Alzheimer's disease (AD) induce inflammatory responses associated with activated microglia and reactive astrocytes, which exacerbate neurodegeneration through release of inflammatory cytokines, reactive oxygen species, and other factors. Inflammation contributes to neurodegeneration at later stages of AD, but it may also play a role in early disease pathogenesis. We found that before plaque deposition, amyloid precursor protein (APP)/presenilin 1 (PSEN1) transgenic mice (PSAPP mice), a well-characterized model of AD, exhibit evidence of cerebrovascular inflammation. Expression of the endothelial cell-specific antigen MECA-32 (mouse endothelial cell antigen-32) was upregulated in the cerebrovasculature of young PSAPP mice (3 months old) and was similar to that observed in mice with experimental autoimmune encephalomyelitis, a model of multiple sclerosis characterized by neuroinflammation. MECA-32 is normally expressed in central and peripheral vasculature throughout development, but expression in the cerebrovasculature is downregulated on establishment of the blood–brain barrier (BBB). However, CNS inflammation triggers re-expression of MECA-32 in compromised cerebrovasculature. Our study indicates that MECA-32 may be a robust marker of cerebrovascular inflammation and compromised BBB integrity, triggered by soluble amyloid-β early in disease pathogenesis.
</description><dc:title>Early cerebrovascular inflammation in a transgenic mouse model of Alzheimer's disease - Corrected Proof</dc:title><dc:creator>Dongzi Yu, Brian Corbett, Yaping Yan, Guang-Xian Zhang, Peter Reinhart, Seongeun J. Cho, Jeannie Chin</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.023</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-03-23</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-03-23</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001340/abstract?rss=yes"><title>A genome-wide search for genetic influences and biological pathways related to the brain's white matter integrity - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001340/abstract?rss=yes</link><description>Abstract: 
A genome-wide search for genetic variants influencing the brain's white matter integrity in old age was conducted in the Lothian Birth Cohort 1936 (LBC1936). At ∼73 years of age, members of the LBC1936 underwent diffusion MRI, from which 12 white matter tracts were segmented using quantitative tractography, and tract-averaged water diffusion parameters were determined (n = 668). A global measure of white matter tract integrity, gFA, derived from principal components analysis of tract-averaged fractional anisotropy measurements, accounted for 38.6% of the individual differences across the 12 white matter tracts. A genome-wide search was performed with gFA on 535 individuals with 542,050 single nucleotide polymorphisms (SNPs). No single SNP association was genome-wide significant (all p &gt; 5 × 10−8). There was genome-wide suggestive evidence for two SNPs, one in ADAMTS18 (p = 1.65 × 10−6), which is related to tumor suppression and hemostasis, and another in LOC388630 (p = 5.08 × 10−6), which is of unknown function. Although no gene passed correction for multiple comparisons in single gene-based testing, biological pathways analysis suggested evidence for an over-representation of neuronal transmission and cell adhesion pathways relating to gFA.
</description><dc:title>A genome-wide search for genetic influences and biological pathways related to the brain's white matter integrity - Corrected Proof</dc:title><dc:creator>Lorna M. Lopez, Mark E. Bastin, Susana Muñoz Maniega, Lars Penke, Gail Davies, Andrea Christoforou, Maria C. Valdés Hernández, Natalie A. Royle, Albert Tenesa, John M. Starr, David J. Porteous, Joanna M. Wardlaw, Ian J. Deary</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.003</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-03-19</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-03-19</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001352/abstract?rss=yes"><title>ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001352/abstract?rss=yes</link><description>Abstract: 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease mainly involving cortical and spinal motor neurons. Several studies indicated that intermediate CAG expansions in ataxin-2 gene (ATXN2) are associated with increased risk of ALS. We analyzed ATXN2 CAG repeats in 658 sporadic ALS patients (SALS), 143 familial ALS cases (FALS), 231 sporadic ataxic subjects, and 551 control subjects. The frequency of ATXN2 alleles with 27–30 repeats was similar in SALS and control subjects. Fifteen SALS subjects carried ≥ 31 CAG repeats. This difference was statistically significant (p = 0.0014). No alleles with ≥ 34 CAG were found. In FALS, the distribution of ATXN2 alleles was similar to control subjects. Our results further contributed in refining CAG-repeat range significantly associated with sporadic ALS. Literature data and our findings indicate that only alleles with ≥ 31 CAG may represent low-penetrance disease/susceptibility alleles associated with variable neurodegenerative phenotypes, including cerebellar ataxia, parkinsonism, and ALS. Overlapping phenotypes should be considered in genetic testing and counseling, both for patients and at-risk family members.
</description><dc:title>ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling - Corrected Proof</dc:title><dc:creator>Cinzia Gellera, Nicola Ticozzi, Viviana Pensato, Lorenzo Nanetti, Alessia Castucci, Barbara Castellotti, Giuseppe Lauria, Franco Taroni, Vincenzo Silani, Caterina Mariotti</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.004</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-03-19</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-03-19</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001534/abstract?rss=yes"><title>Effects of age and β-amyloid on cognitive changes in normal elderly people - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001534/abstract?rss=yes</link><description>Abstract: 
Age-related decline is common in multiple cognitive domains. β-amyloid (Aβ) deposition, a pathological hallmark of Alzheimer's disease, is also associated with cognitive changes in many older people. In this study, we examined a wide range of cognitive function in order to differentiate the effect of age and Aβ on cognition during aging. Using positron emission tomography (PET) imaging with the radiotracer Pittsburgh Compound B (PIB), we classified normal older subjects as High PIB-Old and Low PIB-Old and applied sequential multivariate analyses (i.e., principal components analysis [PCA] and discriminant analysis) to obtain summary measures of cognitive tests encompassing multiple cognitive domains. Among 5 cognitive components, a significant age effect was observed in component scores of visual memory and executive functions, regardless of the level of Aβ. Discriminant scores (weighted scores of the 5 cognitive components) revealed a significant effect of both age and Aβ and were further associated with quantitative PIB counts. The results of the current study highlight both effects of age and Aβ on cognitive changes in normal elderly.
</description><dc:title>Effects of age and β-amyloid on cognitive changes in normal elderly people - Corrected Proof</dc:title><dc:creator>Hwamee Oh, Cindee Madison, Thaddeus J. Haight, Candace Markley, William J. Jagust</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.008</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-03-19</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-03-19</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001558/abstract?rss=yes"><title>Structural and functional neural correlates of visuospatial information processing in normal aging and amnestic mild cognitive impairment - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001558/abstract?rss=yes</link><description>Abstract: 
Our understanding of cognitive changes related to human aging and their underlying neural processes is challenged by the distinction between normal and pathological aging. In our study, the neural correlates of visuospatial working memory (VSWM) in young persons (YC), healthy older adults (HC) and patients with amnestic mild cognitive impairment (aMCI) were investigated. Effects of the genetic risk factor apolipoprotein E (ApoE) ε4 on a VSWM task were analyzed for HC and aMCI patients. Higher cortical activation in extrastriate occipital regions and significantly decreased brain volumes in frontoparietal areas were observed in HC compared with young persons. Also, reduced cortical activation in the right middle frontal gyrus and superior frontal gyrus was observed in aMCI-patients compared with HC. Thus, attenuated cortical activation during VSWM tasks is related to the formation of aMCI and may serve as an early marker for cognitive decline. In contrast to previous studies, no significant apolipoprotein E-linked differences were found between HC and aMCI groups.
</description><dc:title>Structural and functional neural correlates of visuospatial information processing in normal aging and amnestic mild cognitive impairment - Corrected Proof</dc:title><dc:creator>Karolina K. Alichniewicz, Florian Brunner, Hans H. Klünemann, Mark W. Greenlee</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.010</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-03-19</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-03-19</prism:publicationDate></item><item rdf:about="http://www.neurobiologyofaging.org/article/PIIS0197458012001601/abstract?rss=yes"><title>β-Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis - Corrected Proof</title><link>http://www.neurobiologyofaging.org/article/PIIS0197458012001601/abstract?rss=yes</link><description>Abstract: 
Psychosis in Alzheimer disease differentiates a subgroup with more rapid decline, is heritable, and aggregates within families, suggesting a distinct neurobiology. Evidence indicates that greater impairments of cerebral cortical synapses, particularly in dorsolateral prefrontal cortex, may contribute to the pathogenesis of psychosis in Alzheimer disease (AD) phenotype. Soluble β-amyloid induces loss of dendritic spine synapses through impairment of long-term potentiation. In contrast, the Rho guanine nucleotide exchange factor (GEF) kalirin is an essential mediator of spine maintenance and growth in cerebral cortex. We therefore hypothesized that psychosis in AD would be associated with increased soluble β-amyloid and reduced expression of kalirin in the cortex. We tested this hypothesis in postmortem cortical gray matter extracts from 52 AD subjects with and without psychosis. In subjects with psychosis, the β-amyloid1–42/β-amyloid1–40 ratio was increased, due primarily to reduced soluble β-amyloid1–40, and kalirin-7, -9, and -12 were reduced. These findings suggest that increased cortical β-amyloid1–42/β-amyloid1–40 ratio and decreased kalirin expression may both contribute to the pathogenesis of psychosis in AD.
</description><dc:title>β-Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis - Corrected Proof</dc:title><dc:creator>Patrick S. Murray, Caitlin M. Kirkwood, Megan C. Gray, Milos D. Ikonomovic, William R. Paljug, Eric E. Abrahamson, Ruth A. Henteleff, Ronald L. Hamilton, Julia K. Kofler, William E. Klunk, Oscar L. Lopez, Peter Penzes, Robert A. Sweet</dc:creator><dc:identifier>10.1016/j.neurobiolaging.2012.02.015</dc:identifier><dc:source>Neurobiology of Aging (2012)</dc:source><dc:date>2012-03-19</dc:date><prism:publicationName>Neurobiology of Aging</prism:publicationName><prism:publicationDate>2012-03-19</prism:publicationDate></item></rdf:RDF>
